MedTrace Logo

Methamphetamine Isomer Pharmacology in Humans

NCT06746831 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2026-05-05

No results posted yet for this study

Summary

This study is being done to understand the metabolism and impairment profile of methamphetamine (meth). Meth exists as two chemical structures that are mirror images of each other: R-meth and S-meth. S-meth is a strong central nervous system stimulant and used to treat attention deficit disorder (ADD). R-meth is not a strong central nervous system stimulant and is available over-the-counter in nasal decongestant sprays.17 healthy participants will be enrolled for 3 study visits and on study for up to 12 weeks.

Conditions

  • Methamphetamine

Interventions

DRUG

S-(+)-methamphetamine

15 mg

DRUG

R-(-)-methamphetamine

15 mg

DRUG

1:1 racemic mixture of two isomers

15 mg R-Meth + 15 mg S-Meth

Sponsors & Collaborators

Principal Investigators

  • Heather K Barkholtz, PhD · University of Wisconsin, Madison

  • David Leinweber, MD · University of Wisconsin, Madison

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2028-03-31
Completion
2028-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06746831 on ClinicalTrials.gov